Abstract 47P
Background
In CRC molecular studies have shown that there is a great inter-tumour heterogeneity (ITH) within each UICC TNM stage and therefore a range of other transcriptional and protein biomarkers need to be investigated independently of the UICC TNM staging. In CRC, one of these adverse prognostic factors is tumour budding, Typically, tumour budding is assessed using H&E-stained specimens but scoring methods and grading schemes vary widely. A retrospective study was carried out to study the differential expression of discriminative markers in matched invasion fronts and tumour buds of 44 patients with stage 3/4 CRC disease.
Methods
A retrospective study was done on 44 Formalin Fixed paraffin embedded tissue sections with at least stage 3/4 CRC disease. These cases were used to study the expression differences between the central portion of the tumour, the invasion front and the tumour buds using the Luminex bead-based assay. The different tumoral compartments were assessed by a pathologist on a H&E stained slide and a 0.5mm core was obtained from each respective area on the specimen block. The core was lysed for 18 – 22 hrs at 58°C. After overnight incubation, hybridization-based assay was performed to study the expression of 50 different genes. Data analysis was carried out to see if there is any statistically significant difference between the central portion of the tumour, the invasion front and tumour buds.
Results
A statistically significant differences was noted in the expression of TRIB1 and CCND3 when comparing the central portion of the tumour to the tumour buds. The expression of TRIB1 and CCND3was higher in the buds than that of the central tumour. A statistically significant difference was seen in the expression of CDX2 when comparing the invasion front to the tumour bud. CDX2 was higher in the invasion front than in the tumour buds. A statistically significant difference was also seen in the expression of MCL1 which was higher in the invasion fronts when compared to the central tumour part.
Conclusions
With the use of a bead based multiplex assay we were able to carry out differential expression of a number of genes related to invasiveness, metastasis and treatment resistance in matched central tumour, invasion fronts and tumour buds in CRC patients.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
Emanuele Cancer Research Foundation Malta.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
146P - The prognosis value of heat-shock proteins in esophagogastric cancer: A systematic review and meta-analysis
Presenter: Eric Nakamura
Session: Cocktail & Poster Display session
Resources:
Abstract
148P - Identification of potential predictive biomarkers for ovarian cancer chemotherapy response
Presenter: Alsina Nurgalieva
Session: Cocktail & Poster Display session
Resources:
Abstract
149P - Rare RAS mutations are associated with recurrence patterns and recurrence-free survival in colon cancer: First results from Morocco
Presenter: Fatima Agy
Session: Cocktail & Poster Display session
Resources:
Abstract
151P - Development of a predictive model for response to neoadjuvant chemoradiation therapy of rectal cancer using the immunologic profile
Presenter: Eun Shin
Session: Cocktail & Poster Display session
Resources:
Abstract
152P - Biomarkers of neoadjuvant chemoradiotherapy response in locally advanced rectal cancer
Presenter: Cibele Masotti
Session: Cocktail & Poster Display session
Resources:
Abstract
153P - BRAF variants and therapy outcomes in melanoma
Presenter: Eftychia Chatziioannou
Session: Cocktail & Poster Display session
Resources:
Abstract
154P - The impact of proton pump inhibitors in the prognosis of patients with non-metastatic nasopharyngeal carcinoma
Presenter: João Barbosa Martins
Session: Cocktail & Poster Display session
Resources:
Abstract
155P - Use of machine learning for the identification of molecular biomarkers to predict response to neoadjuvant chemotherapy in locally advanced breast cancer patients
Presenter: María Del Río Pisula
Session: Cocktail & Poster Display session
Resources:
Abstract
156P - Molecularly driven therapy recommended by a molecular tumor board: Accessible option or privilege for a minority of patients? A single-center experience from the Czech Republic
Presenter: Michal Eid
Session: Cocktail & Poster Display session
Resources:
Abstract
157P - PCM4EU academy: An educational program for precision oncology
Presenter: Loic Verlingue
Session: Cocktail & Poster Display session
Resources:
Abstract